ImClone Hammered as Sales Lag Estimates

ImClone Hammered as Sales Lag Estimates
Scandal-plagued ImClone Systems may have fallen off the road to recovery.
While the company’s second-quarter earnings beat Wall Street estimates, the stock plunged yesterday on disappointing sales of the company’s key cancer drug.

Click here for reuse options!
Copyright 2004 Biotechblog

Leave a Reply

%d bloggers like this: